Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Buy
70
JPM Quote, Financials, Valuation and Earnings
Last price:
$281.14
Seasonality move
:
0.2%
Day range:
$272.11 - $278.55
52-week range:
$190.90 - $280.25
Dividend yield:
1.82%
P/E ratio:
13.66x
P/S ratio:
4.60x
P/B ratio:
2.33x
Volume:
8.1M
Avg. volume:
8M
1-year change:
41.76%
Market cap:
$773.3B
Revenue:
$169.4B
EPS (TTM):
$20.37
Analysts' Opinion
-
Consensus RatingJPMorgan Chase & has received a consensus rating of Hold. The company's average rating is a Hold based on 8 Buy ratings, 9 Hold ratings, and 1 Sell rating.
-
Price Target DownsideAccording to analysts' consensus price target of $270.58, JPMorgan Chase & has an estimated downside of -2.76% from its current price of $278.27.
-
Price Target UpsideAccording to analysts, the highest upside price target is $330.00 representing 18.59% upside increase from its current price of $278.27.
Fair Value
-
According to the consensus of 18 analysts, JPMorgan Chase & has -2.76% downside to fair value with a price target of $270.58 per share.
JPM vs. S&P 500
-
Over the past 5 trading days, JPMorgan Chase & has overperformed the S&P 500 by 4.26% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
JPMorgan Chase & does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
JPMorgan Chase & has grown year-over-year revenues for 12 quarters straight. In the most recent quarter JPMorgan Chase & reported revenues of $45.3B.
Earnings Growth
-
JPMorgan Chase & has grown year-over-year earnings for 5 quarters straight. In the most recent quarter JPMorgan Chase & reported earnings per share of $5.07.
Enterprise value:
451.7B
EV / Invested capital:
0.55x
Price / LTM sales:
4.60x
EV / EBIT:
2.56x
EV / Revenue:
2.61x
PEG ratio (5yr expected):
0.59x
EV / Free cash flow:
-3.23x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
1.44%
Net Income Margin (TTM):
34.54%
Return On Equity:
17.36%
Return On Invested Capital:
7.48%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $135.4B | $158.9B | $172.8B | $41.9B | $45.3B | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $13.55 | $16.56 | $20.37 | $4.44 | $5.07 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4T | $1.5T | $1.2T | $1.2T | $1.4T | |
| Total Assets | $3.7T | $4T | $3.7T | $4.1T | $4.4T | |
| Current Liabilities | $419.4B | $339.2B | $333.3B | $407.9B | $635.3B | |
| Total Liabilities | $3.4T | $3.7T | $3.4T | $3.8T | $4T | |
| Total Equity | $280.7B | $285.9B | $303.1B | $336.6B | $351.4B | |
| Total Debt | $334.4B | $350.8B | $337.7B | $442.1B | $472.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $37.8B | -$29.9B | -$139.7B | -$154.2B | -$251.8B | |
| Cash From Investing | -$41.4B | $470M | -$238.1B | -$43.4B | -$118.1B | |
| Cash From Financing | -$194.5B | $51B | $240.3B | $141.2B | $318.1B | |
| Free Cash Flow | $37.8B | -$29.9B | -$139.7B | -$154.2B | -$251.8B | |
JPM
Sector
Market Cap
$773.3B
$620M
Price % of 52-Week High
99.29%
86.64%
Dividend Yield
1.82%
2.06%
Shareholder Yield
4.36%
4.11%
1-Year Price Total Return
41.76%
11.29%
Beta (5-Year)
1.085
0.594
Dividend yield:
1.82%
Annualized payout:
$4.60
Payout ratio:
25.32%
Growth streak:
11 years
Technicals
8-day SMA
Buy
Level
$271.06
200-day SMA
Buy
Level
$242.97
Bollinger Bands (100)
Buy
Level
237.56 - 270.24
Chaikin Money Flow
Buy
Level
1.8B
20-day SMA
Buy
Level
$267.22
Relative Strength Index (RSI14)
Buy
Level
71.41
ADX Line
Buy
Level
20.55
Williams %R
Sell
Level
-1.5351
50-day SMA
Buy
Level
$255.93
MACD (12, 26)
Buy
Level
4.73
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Sell
Level
-1.1B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.611)
Sell
CA Score
(Annual)
Level (-2.1508)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.5458)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with nearly $4 trillion in assets. It is organized into four major segments: consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates, and is subject to regulation, in multiple countries.
Stock Forecast FAQ
In the current month, JPM has received 8 Buy ratings 9 Hold ratings, and 1 Sell ratings. The JPM average analyst price target in the past 3 months is $270.58.
-
Where Will JPMorgan Chase & Stock Be In 1 Year?
According to analysts, the consensus estimate is that JPMorgan Chase & share price will drop to $270.58 per share over the next 12 months.
-
What Do Analysts Say About JPMorgan Chase &?
Analysts are divided on their view about JPMorgan Chase & share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that JPMorgan Chase & is a Sell and believe this share price will rise from its current level to $195.00.
-
What Is JPMorgan Chase &'s Price Target?
The price target for JPMorgan Chase & over the next 1-year time period is forecast to be $270.58 according to 18 Wall Street analysts, 8 of them rate the stock a Buy, 1 rates the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is JPM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for JPMorgan Chase & is a Hold. 9 of 18 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of JPM?
You can purchase shares of JPMorgan Chase & via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase JPMorgan Chase & shares.
-
What Is The JPMorgan Chase & Share Price Today?
JPMorgan Chase & was last trading at $281.14 per share. This represents the most recent stock quote for JPMorgan Chase &. Yesterday, JPMorgan Chase & closed at $278.27 per share.
-
How To Buy JPMorgan Chase & Stock Online?
In order to purchase JPMorgan Chase & stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Howard Marks Buy Grab Stock?
When a legendary value investor who cut his teeth in…
Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 3.18% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 2.26% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 13.99% over the past day.
